## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.3% in mid entry zone (3.0-6.0%), top 10% cross-sectional ranking. Short-term MRS_5 (3.6%) confirms momentum alignment. Strong momentum (+5.1% 5-day acceleration). Outperforming sector by 7.3%. Caution: overbought RSI (77).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($142.19)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Kymera Therapeutics launches $500 million public offering**
- Source: Investing.com | 20251208T211007 | Neutral | Relevance: 64%
- Kymera Therapeutics, Inc. announced a $500 million underwritten public offering of its common stock, with underwriters having a 30-day option for an additional $75 million in shares. Despite the company being overvalued according to InvestingPro data, it holds a "Strong Buy" recommendation from analysts and boasts substantial liquidity. The proceeds will fund the advancement of its protein degrader programs for immunological diseases and serve general corporate purposes.

**2. FedEx stock price target raised to $290 from $280 at Wells Fargo**
- Source: Investing.com | 20251208T114616 | Neutral | Relevance: 64%
- Wells Fargo has increased its price target for FedEx (NYSE:FDX) to $290 from $280 while maintaining an "Equal Weight" rating. Despite strong parcel fundamentals and projections for FedEx to exceed market expectations, Wells Fargo expressed caution due to macroeconomic uncertainty, weakness in the LTL segment, and the company's intention to manage expectations carefully. The firm noted that FedEx's stock has already seen a significant run-up of 26.5% over the past six months and is currently trading slightly above its calculated Fair Value according to InvestingPro data.

**3. Life360 director Coghlan sells $241k in shares By Investing.com**
- Source: Investing.com Australia | 20251210T020924 | Somewhat-Bullish | Relevance: 62%
-  John Philip Coghlan, a director at Life360, Inc., recently sold 3,125 shares of the company's common stock for approximately $241,316. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock has shown significant returns year-to-date and over the past year, though InvestingPro's Fair Value estimate suggests it might be overvalued.

**4. Diageo plc $DEO Shares Bought by Federated Hermes Inc.**
- Source: MarketBeat | 20251209T031008 | Neutral | Relevance: 62%
- Federated Hermes Inc. increased its stake in Diageo plc (NYSE:DEO) by 7.3% during the second quarter, valuing its holdings at approximately $68.34 million. Despite this, analyst sentiment remains mixed-to-negative, with an average rating of "Reduce" and a consensus target price of $119. The company's stock currently trades at $88.38, below its 50-day and 200-day simple moving averages, reflecting recent downward trends and analyst downgrades.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Piper Sandler | $135 | $155 | -13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Piper Sandler | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Long-term trend broken: trading 8.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $25.9B |
| Beta | 0.46 |
| 52W Range | $126.45 - $244.69 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 12.0 |
| Current P/E | 12.9 |
| YoY Growth | 8.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from 0.1% to 5.3% (+5.1% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 90th percentile. MRS_5 at 3.6% confirms short-term momentum alignment. Outperforming sector by 7.3pp, stock-specific strength. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.66), confirming momentum. RSI overbought at 77, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.26% (CS: 90) | Strong |
| RSI_14 | 76.9 | Overbought |
| MACD Histogram | 1.66 | Bullish |
| vs SMA20 | 1.097x | Above |
| vs SMA50 | 1.091x | Above |
| vs SMA200 | 0.916x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $148.51
- **Stop Loss:** $142.19 (4.3% risk)
- **Target:** $157.99 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $11,732.29
- **Portfolio %:** 11.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*